Company intelligence / Profile preview

Traversa Therapeutics

La Jolla, California, USA

Ownership: Private
Development stage: Other

Overview

Traversa Therapeutics was a biotechnology company focused on developing a proprietary delivery platform for RNA interference (RNAi) therapeutics. The company's core technology utilized Protein Transduction Domains (PTDs), also known as cell-penetrating peptides, to enable the systemic delivery of small interfering RNA (siRNA) into target cells. By overcoming the significant challenge of intracellular delivery, Traversa aimed to treat various diseases, including cancer and inflammatory conditions. Despite securing significant venture capital and a research collaboration with Pfizer, the company ceased operations around 2012.

Therapeutic areas: OncologyImmunology
Modalities: RNA therapySmall interfering RNAPeptides
Industry: Biotech

Partnerships

Pfizer

Beyond the preview

Go deeper on Traversa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Traversa Therapeutics.

Explore the full profile